TA
ALXN

Thor Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Thor Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$34K Buy
+248
New +$30.8K 0.42% 112

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Thor Advisors's ALXN Position: Q1 2019 in Review

Thor Advisors opened a new position in Alexion Pharmaceuticals (ALXN) in Q1 2019: 248 shares worth $34K. The stake represents 0.42% of the portfolio and ranks #112 among its holdings.

611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Thor Advisors held 248 shares of Alexion Pharmaceuticals worth $34K as of Q1 2019.
  • Alexion Pharmaceuticals was a new Thor Advisors position in Q1 2019.
  • Alexion Pharmaceuticals made up 0.42% of Thor Advisors's portfolio in Q1 2019, its #112 holding.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Thor Advisors's 13F filing for Q1 2019, filed 12 Jun 2019.